



Canada's Drug Agency
L'Agence des médicaments du Canada
Drugs, Health Technologies and Systems. Médicaments, technologies de la santé et systèmes.

Canada's Drug Agency (CDA-AMC) is a pan-Canadian health organization. Created and funded by Canada's federal, provincial, and territorial governments, we're responsible for driving better coordination, alignment, and public value within Canada's drug and health technology landscape. We provide Canada's health system leaders with independent evidence and advice so they can make informed drug, health technology, and health system decisions, and we collaborate with national and international partners to enhance our collective impact.

The CDA-AMC **Scientific Advice program** is a voluntary, fee-for-service consultation offered to pharmaceutical companies to provide advice on early drug development plans from a health technology assessment perspective. Scientific Advice is provided at the request of the applicant. The application for Scientific Advice constitutes the applicant's agreement with the program policies, guidelines, and processes, including this disclaimer.

Disclaimer: CDA-AMC has taken care to ensure that the information in this document was accurate, complete, and up to date when it was provided but does not make any guarantee to that effect. CDA-AMC is not responsible for any errors, omissions, injury, loss, or damage arising from or as a result of the use (or misuse) of any information contained in or implied by the Scientific Advice or any of the source materials.

The Scientific Advice provided to the applicant is not binding and will not be considered relevant for any future assessments or recommendations related to the drug for which Scientific Advice is sought. Advice should not be considered representative of any future CDA-AMC position. The Scientific Advice program operates independently from other CDA-AMC programs, as well as from the Health Canada regulatory process. Advice provided to applicants is without prejudice to any intellectual property rights of third parties.

The copyright and other intellectual property rights in this document are owned by the Canadian Agency for Drugs and Technologies in Health (operating as CDA-AMC) and its licensors. You may only use, download, print, or copy this document within your organization; you may not modify or disseminate this document; and you must give appropriate credit to CDA-AMC and its licensors.